Legend Biotech stock had its Relative Strength (RS) Rating upgraded from 87 to 91 Thursday.
As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength. This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the last 52 weeks holds up against all the other stocks in our database.
History reveals that the market's biggest winners tend to have an 80 or better RS Rating as they launch their biggest runs.
Looking For Winning Stocks? Try This Simple Routine
Is Legend Biotech Stock A Buy?
Legend Biotech stock is not currently offering a proper buying opportunity. See if the stock goes on to form a sound pattern that could launch a new move.
Top and bottom line growth moved higher in the company's most recent quarter. Earnings were up 16%, compared to 0% in the prior report. Revenue increased from -4% to 198%.
Legend Biotech Corp earns the No. 116 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharma, Genmab and Vertex Pharmaceuticals are among the top 5 highly rated stocks within the group. For more industry news, check out "
Biotech And Pharmaceutical Industry And Stock News."
